Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management

Bipolar Disorders

Volumn 21, Issue 7, 2019, Pages 650-659

  Post, Robert M ^a   Yatham, Lakshmi N ^b,c   Vieta, Eduard ^d   Berk, Michael ^e,f,g   Nierenberg, Andrew A ^h  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

^e DEAKIN UNIVERSITY   (Australia)

^f THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

anticonvulsants; anxiety comorbidity; atypical antipsychotics; childhood onset bipolar disorders; disruptive behavioral disorders; lithium; stimulants; substance abuse

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CARIPRAZINE; FOLIC ACID; KETAMINE; LAMOTRIGINE; LITHIUM SALT; LURASIDONE; MOOD STABILIZER; NIMODIPINE; QUETIAPINE; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANK3 PROTEIN, HUMAN; ANKYRIN; ANTICONVULSIVE AGENT; CACNA1C PROTEIN, HUMAN; CALCIUM CHANNEL L TYPE; LITHIUM DERIVATIVE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; NEUROLEPTIC AGENT; TRANQUILIZER;

ALLELE; ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; DRUG BLOOD LEVEL; DRUG SAFETY; EVIDENCE BASED MEDICINE; FAMILY; GENETIC SCREENING; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MANIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOEDUCATION; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION; RISK REDUCTION; SUBSTANCE ABUSE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COMBINATION DRUG THERAPY; DRUG DEPENDENCE; DRUG MONITORING; ELECTROCONVULSIVE THERAPY; GENETICS; HOMOCYSTINURIA; PRACTICE GUIDELINE; PSYCHOSIS; SECONDARY PREVENTION; SMOKING CESSATION; SPASTICITY; TRANSCRANIAL MAGNETIC STIMULATION;

ANKYRINS; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; CALCIUM CHANNELS, L-TYPE; CARDIOVASCULAR DISEASES; CLINICAL DECISION-MAKING; COMORBIDITY; DRUG MONITORING; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; EVIDENCE-BASED MEDICINE; EXCITATORY AMINO ACID ANTAGONISTS; GENETIC TESTING; HOMOCYSTINURIA; HUMANS; KETAMINE; LITHIUM COMPOUNDS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUSCLE SPASTICITY; PRACTICE GUIDELINES AS TOPIC; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; SECONDARY PREVENTION; SMOKING CESSATION; SUBSTANCE-RELATED DISORDERS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 85070829799     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12813     Document Type: Article

References (57)

1. Nierenberg A. Moving forward by learning from a learning healthcare system. Psychiatric Annals. 2018;48(8):356.
2. Goodwin F, Redfield K. Manic-depressive illness. In: Bipolar Disorders and Recurrent Depression. 2 edn. Oxford, England, UK: Oxford University Press; 2009.
3. Post RM, Leverich GL. Treatment of Bipolar Illness: A Casebook for Clinicians and Patients; New York, NY: WW Norton and Company; 2008:1-666.
4. Carvalho AF, Vieta E. Integrative clinical strategies and future directions. In: Carvalho AF, Vieta E, eds. The Treatment of Bipolar Disorder. Oxford, England, UK: Oxford University Press; 2017.
5. Yatham L, Kennedy S, Parikh S, Schaffer A.2018 guideline for the management of patients with bipolar disorder. Canadian Network for Mood and Anxiety Treatments (CANMAT)/International Society for Bipolar Disorders (ISBD); 2018; Amsterdam.
6. Kessing LV, Hansen HV, Hvenegaard A, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202(3):212-219.
7. Berk M, Post R, Ratheesh A, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry. 2017;16(3):236-244.
8. Berk M, Daglas R, Dandash O, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry. 2017;210(6):413-421.
9. Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry. 2014;205(3):214-220.
10. Wapner J, Weinberg RA. The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level. New York, NY: The Experiment Distributed by Workman Pub. Co.; 2013.
11. Bortolasci CC, Spolding B, Callaly E, et al. Mechanisms underpinning the polypharmacy effects of medications in psychiatry. Int J Neuropsychopharmacol. 2018;21(6):582-591.
12. Choudhry HR, Khan R, Shebbir A, Mulfti KA. Nimodipine in the treatment of bipolar disorder. Biol Psychiat. 2010;67.
13. Pazzaglia PJ, Post R, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapdi cycling affective dysregulation. Psychiatry Res. 1993;49(3):257-272.
14. Davanzo PA, Krah N, Kleiner J, McCracken J. Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness. J Child Adolesc Psychopharmacol. 1999;9(1):51-61.
15. Zhu S, Cordner ZA, Xiong J, et al. Genetic disruption of ankyrin-G in adult mouse forebrain causes cortical synapse alteration and behavior reminiscent of bipolar disorder. Proc Natl Acad Sci USA. 2017;114(39):10479-10484.
16. Post RM. The new news about lithium: an underutilized treatment in the United States. Neuropsychopharmacology. 2018;43:1174-1179.
17. Data-Franco J, Berk M. The nocebo effect: a clinicians guide. Aust N Z J Psychiatry. 2013;47(7):617-623.
18. Post RM. Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention. Bipolar Disord. 2016;18(4):315-324.
19. Nasca C, Xenos D, Barone Y, et al. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA. 2013;110(12):4804-4809.
20. Kemp DE, Schinagle M, Gao K, et al. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014;28(6):571-581.
21. O’Neil A, Berk M, Itsiopoulos C, et al. A randomised, controlled trial of a dietary intervention for adults with major depression (the "SMILES" trial): study protocol. BMC psychiatry. 2013;13:114.
22. Salagre E, Fernandes BS, Dodd S, Brownstein DJ, Berk M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Affect Disord. 2016;200:235-242.
23. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014;348:g1151.
24. Post RM, Leverich GS, Kupka R, et al. Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. Compr Psychiatry. 2016;66:146-156.
25. Passmore MJ, Garnham J, Duffy A, et al. Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. Bipolar Disord. 2003;5(2):110-114.
26. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology. 2000;42(Suppl. 1):2-10.
27. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord. 2005;85(3):259-266.
28. Vieta E, Goikolea JM, Martínez-Arán A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry. 2006;67(3):473-477.
29. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70-77.
30. Post RM, Ketter TA, Joffe RT, Kramlinger KL. Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol. 1991;6(4):197-207.
31. Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry. 2013;202(3):172-176.
32. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder–a double-blind randomized placebo-controlled trial. Biol Psychiat. 2008;64(6):468-475.
33. Ellegaard PK, Licht RW, Poulsen HE, et al. Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). Int J Bipolar Disord. 2018;6(1):11.
34. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986;10(1):9-13.
35. Geddes JR, Gardiner A, Rendell J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 x 2 factorial randomised trial. Lancet Psychiatry. 2016;3(1):31-39.
36. Nierenberg AA, Montana R, Kinrys G, Deckersbach T, Dufour S, Baek JH. Bipolar I depressive episodes: an open trial proof-of-concept registry. J Affect Disord. 2017;207:429-433.
37. Berk M, Jacka FN, Williams LJ, Ng F, Dodd S, Pasco JA. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. Aust N Z J Psychiatry. 2008;42(10):874-878.
38. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. Br J Psychiatry. 2011;198(5):357-364.
39. McGrath JJ. Vitamin D and mental health - the scrutiny of science delivers a sober message. Acta Psychiatr Scand. 2017;135(3):183-184.
40. Dean OM, Kanchanatawan B, Ashton M, et al. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. Aust N Z J Psychiatry. 2017;51(8):829-840.
41. Halaris A. Modulation of immune system activation may arrest neuroprogression in bipolar disorder. Biol Psychiat. 2017;81(10):S314-S314.
42. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41.
43. McGirr A, Karmani S, Arsappa R, et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression. World Psychiatry. 2016;15(1):85-86.
44. Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683-1692.
45. Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172(1):41-51.
46. Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry. 2017;174(7):640-648.
47. Freedman R, Brown AS, Cannon TD, et al. Can a Framework Be Established for the Safe Use of Ketamine? Am J Psychiatry. 2018;175(7):587-589.
48. Berk M, Loo C, Davey CG, Harvey BH. Ketamine and rapidly acting antidepressants: Breaking the speed of sound or light? Aust N Z J Psychiatry. 2018;52(11):1026-1029.
49. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136(1–2):163-166.
50. Nasca C, Bigio B, Lee FS, et al. Acetyl-L-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci USA. 2018.
51. Post RM. Myriad of implications of acetyl-l-carnitine deficits in depression. Proc Natl Acad Sci USA. 2018;115(34):8475-8477.
52. Sanchez-Moreno J, Martinez-Aran A, Vieta E. Treatment of functional impairment in patients with bipolar disorder. Curr Psychiatry Rep. 2017;19(1):3.
53. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
54. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 2004;6(6):504-518.
55. Post RM. Treatment of bipolar depression: evolving recommendations. Psychiatr Clin North Am. 2016;39(1):11-33.
56. Post RM. New perspectives on the course and treatment of bipolar disorder. Minerva Med. 2017;58(1):40-53.
57. Post RM, Altshuler LL, Frye M, et al. Complexity of pharmacological treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry. 2010;71(9):1176-1186.